Exciting Progress for Difficult-to-Treat Advanced Melanoma — What to Know About Biologic Drug Brenetafusp

The Latest on Biologic Drug, Brenetafusp

An exciting biologic drug called brenetafusp is being studied, and showing real promise, in treating advanced cutaneous melanoma.
Dr. Mohammed Dar, Chief Medical Officer and Head of Clinical Development at Immunocore, told SurvivorNet that early data suggests brenetafusp can significantly delay disease progression for patients with advanced cutaneous melanoma who have exhausted other treatment options.
“The way that brenetafusp works is that it’s called a bispecific, so it has two ends,” Dr. Dar explained. “One end targets the cancer and then the other end connects to immune cells that are passing by and forms a bridge between the immune cell and the cancer cell. That bridge triggers the immune cell to kill the cancer cell.”
In a phase I study, more than half of patients had their disease stop growing. “On average, the disease control lasted for about six months,” Dr. Dar explained.